-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
According to a report released by international accounting firm PricewaterhouseCoopers on the 7th, the number of mergers and acquisitions in China's pharmaceutical and life science industries will reach 1,253 in 2021, with a transaction value of US$44.
5 billion
.
5 billion
.
Tang Xun, partner of PwC China's M&A service, said that in 2021, the M&A and transaction market in China's pharmaceutical and life science industries will remain hot, mainly due to the continuous impact of repeated epidemics.
New policies in various regions encourage innovation and segment the track.
The comprehensive impact of successively entering into phased adjustments and other reasons
.
New policies in various regions encourage innovation and segment the track.
The comprehensive impact of successively entering into phased adjustments and other reasons
.
The report pointed out that transactions in the fields of innovation-oriented biomedicine and biotechnology (such as immune cell therapy products, mRNA vaccines, etc.
) are still investment hotspots in the pharmaceutical industry
.
) are still investment hotspots in the pharmaceutical industry
.
Fei Ying, Partner of PwC China M&A Services, pointed out that under the influence of China's aging population, coupled with the continuous advancement of medical insurance negotiations and the state's centralized procurement , the state's policy of encouraging new drug R&D and innovation continues to drive pharmaceutical companies to continue to innovate and transform, and promote pharmaceutical companies .
The merger and reorganization of production and distribution enterprises has accelerated the financing and mergers and acquisitions in the pharmaceutical field; the number of transactions in the pharmaceutical sector in 2021 will increase by 23% compared with 2020 to 782, with a transaction value of approximately US$34.
4 billion
.
Traditional pharmaceuticals, vaccines, blood products and other segments of biopharmaceuticals and cellular immunotherapy dominate head deals
.
The merger and reorganization of production and distribution enterprises has accelerated the financing and mergers and acquisitions in the pharmaceutical field; the number of transactions in the pharmaceutical sector in 2021 will increase by 23% compared with 2020 to 782, with a transaction value of approximately US$34.
4 billion
.
Traditional pharmaceuticals, vaccines, blood products and other segments of biopharmaceuticals and cellular immunotherapy dominate head deals
.
In terms of medical devices , Fei Ying said that in 2021, domestic substitution will be accelerated, the innovation and development of high-end medical devices such as medical imaging will be rapid, the subdivision track pattern will be adjusted, and the consumption-based medical beauty-related products will grow significantly
.
In 2021, the number of M&A transactions in the medical device sector will reach 471, a significant increase of 60% compared with 2020, and the transaction value will reach US$10.
1 billion, an increase of 26% compared with 2020 and a new high in the past five years
.
.
In 2021, the number of M&A transactions in the medical device sector will reach 471, a significant increase of 60% compared with 2020, and the transaction value will reach US$10.
1 billion, an increase of 26% compared with 2020 and a new high in the past five years
.
In 2021, the overseas M&A transactions of Chinese enterprises and the inbound investment of foreign investors will also rebound to varying degrees, and the number and amount of transactions will increase compared with the previous two years
.
With the continuation of the new crown epidemic, the report believes that the internationalization of domestic equipment is expected to usher in rapid development, and overseas mergers and acquisitions will generate a new round of opportunities
.
.
With the continuation of the new crown epidemic, the report believes that the internationalization of domestic equipment is expected to usher in rapid development, and overseas mergers and acquisitions will generate a new round of opportunities
.
The report predicts that China's aging population and the impact of the new crown epidemic will continue to increase market demand in the pharmaceutical and life science industries, and the long-term trend will remain positive
.
With the support and encouragement of the state for pharmaceutical innovation, the process of domestic substitution of imported devices is intensified, which further promotes the integration of industry enterprises and the process of investment and financing, and the industry's mergers and acquisitions investment will remain active for a long time
.
(Finish)
.
With the support and encouragement of the state for pharmaceutical innovation, the process of domestic substitution of imported devices is intensified, which further promotes the integration of industry enterprises and the process of investment and financing, and the industry's mergers and acquisitions investment will remain active for a long time
.
(Finish)
According to a report released by international accounting firm PricewaterhouseCoopers on the 7th, the number of mergers and acquisitions in China's pharmaceutical and life science industries will reach 1,253 in 2021, with a transaction value of US$44.
5 billion
.
5 billion
.
Tang Xun, partner of PwC China's M&A service, said that in 2021, the M&A and transaction market in China's pharmaceutical and life science industries will remain hot, mainly due to the continuous impact of repeated epidemics.
New policies in various regions encourage innovation and segment the track.
The comprehensive impact of successively entering into phased adjustments and other reasons
.
New policies in various regions encourage innovation and segment the track.
The comprehensive impact of successively entering into phased adjustments and other reasons
.
The report pointed out that transactions in the fields of innovation-oriented biomedicine and biotechnology (such as immune cell therapy products, mRNA vaccines, etc.
) are still investment hotspots in the pharmaceutical industry
.
) are still investment hotspots in the pharmaceutical industry
.
Fei Ying, Partner of PwC China M&A Services, pointed out that under the influence of China's aging population, coupled with the continuous advancement of medical insurance negotiations and the state's centralized procurement , the state's policy of encouraging new drug R&D and innovation continues to drive pharmaceutical companies to continue to innovate and transform, and promote pharmaceutical companies .
The merger and reorganization of production and distribution enterprises has accelerated the financing and mergers and acquisitions in the pharmaceutical field; the number of transactions in the pharmaceutical sector in 2021 will increase by 23% compared with 2020 to 782, with a transaction value of approximately US$34.
4 billion
.
Traditional pharmaceuticals, vaccines, blood products and other segments of biopharmaceuticals and cellular immunotherapy dominate head deals
.
The merger and reorganization of production and distribution enterprises has accelerated the financing and mergers and acquisitions in the pharmaceutical field; the number of transactions in the pharmaceutical sector in 2021 will increase by 23% compared with 2020 to 782, with a transaction value of approximately US$34.
4 billion
.
Traditional pharmaceuticals, vaccines, blood products and other segments of biopharmaceuticals and cellular immunotherapy dominate head deals
.
In terms of medical devices , Fei Ying said that in 2021, domestic substitution will be accelerated, the innovation and development of high-end medical devices such as medical imaging will be rapid, the subdivision track pattern will be adjusted, and the consumption-based medical beauty-related products will grow significantly
.
In 2021, the number of M&A transactions in the medical device sector will reach 471, a significant increase of 60% compared with 2020, and the transaction value will reach US$10.
1 billion, an increase of 26% compared with 2020 and a new high in the past five years
.
.
In 2021, the number of M&A transactions in the medical device sector will reach 471, a significant increase of 60% compared with 2020, and the transaction value will reach US$10.
1 billion, an increase of 26% compared with 2020 and a new high in the past five years
.
In 2021, the overseas M&A transactions of Chinese enterprises and the inbound investment of foreign investors will also rebound to varying degrees, and the number and amount of transactions will increase compared with the previous two years
.
With the continuation of the new crown epidemic, the report believes that the internationalization of domestic equipment is expected to usher in rapid development, and overseas mergers and acquisitions will generate a new round of opportunities
.
.
With the continuation of the new crown epidemic, the report believes that the internationalization of domestic equipment is expected to usher in rapid development, and overseas mergers and acquisitions will generate a new round of opportunities
.
The report predicts that China's aging population and the impact of the new crown epidemic will continue to increase market demand in the pharmaceutical and life science industries, and the long-term trend will remain positive
.
With the support and encouragement of the state for pharmaceutical innovation, the process of domestic substitution of imported devices is intensified, which further promotes the integration of industry enterprises and the process of investment and financing, and the industry's mergers and acquisitions investment will remain active for a long time
.
(Finish)
.
With the support and encouragement of the state for pharmaceutical innovation, the process of domestic substitution of imported devices is intensified, which further promotes the integration of industry enterprises and the process of investment and financing, and the industry's mergers and acquisitions investment will remain active for a long time
.
(Finish)
According to a report released by international accounting firm PricewaterhouseCoopers on the 7th, the number of mergers and acquisitions in China's pharmaceutical and life science industries will reach 1,253 in 2021, with a transaction value of US$44.
5 billion
.
5 billion
.
Tang Xun, partner of PwC China's M&A service, said that in 2021, the M&A and transaction market in China's pharmaceutical and life science industries will remain hot, mainly due to the continuous impact of repeated epidemics.
New policies in various regions encourage innovation and segment the track.
The comprehensive impact of successively entering into phased adjustments and other reasons
.
New policies in various regions encourage innovation and segment the track.
The comprehensive impact of successively entering into phased adjustments and other reasons
.
The report pointed out that transactions in the fields of innovation-oriented biomedicine and biotechnology (such as immune cell therapy products, mRNA vaccines, etc.
) are still investment hotspots in the pharmaceutical industry
.
) are still investment hotspots in the pharmaceutical industry
.
Fei Ying, Partner of PwC China M&A Services, pointed out that under the influence of China's aging population, coupled with the continuous advancement of medical insurance negotiations and the state's centralized procurement , the state's policy of encouraging new drug R&D and innovation continues to drive pharmaceutical companies to continue to innovate and transform, and promote pharmaceutical companies .
The merger and reorganization of production and distribution enterprises has accelerated the financing and mergers and acquisitions in the pharmaceutical field; the number of transactions in the pharmaceutical sector in 2021 will increase by 23% compared with 2020 to 782, with a transaction value of approximately US$34.
4 billion
.
Traditional pharmaceuticals, vaccines, blood products and other segments of biopharmaceuticals and cellular immunotherapy dominate head deals
.
Purchasing Purchasing Purchasing Medicines Medicines Medicines Medicines Medicines MedicinesThe merger and reorganization of production and distribution enterprises has accelerated the financing and mergers and acquisitions in the pharmaceutical field; the number of transactions in the pharmaceutical sector in 2021 will increase by 23% compared with 2020 to 782, with a transaction value of approximately US$34.
4 billion
.
Traditional pharmaceuticals, vaccines, blood products and other segments of biopharmaceuticals and cellular immunotherapy dominate head deals
.
In terms of medical devices , Fei Ying said that in 2021, domestic substitution will be accelerated, the innovation and development of high-end medical devices such as medical imaging will be rapid, the subdivision track pattern will be adjusted, and the consumption-based medical beauty-related products will grow significantly
.
In 2021, the number of M&A transactions in the medical device sector will reach 471, a significant increase of 60% compared with 2020, and the transaction value will reach US$10.
1 billion, an increase of 26% compared with 2020 and a new high in the past five years
.
medical device medical device medical device.
In 2021, the number of M&A transactions in the medical device sector will reach 471, a significant increase of 60% compared with 2020, and the transaction value will reach US$10.
1 billion, an increase of 26% compared with 2020 and a new high in the past five years
.
In 2021, the overseas M&A transactions of Chinese enterprises and the inbound investment of foreign investors will also rebound to varying degrees, and the number and amount of transactions will increase compared with the previous two years
.
With the continuation of the new crown epidemic, the report believes that the internationalization of domestic equipment is expected to usher in rapid development, and overseas mergers and acquisitions will generate a new round of opportunities
.
enterprise enterprise enterprise.
With the continuation of the new crown epidemic, the report believes that the internationalization of domestic equipment is expected to usher in rapid development, and overseas mergers and acquisitions will generate a new round of opportunities
.
The report predicts that China's aging population and the impact of the new crown epidemic will continue to increase market demand in the pharmaceutical and life science industries, and the long-term trend will remain positive
.
With the support and encouragement of the state for pharmaceutical innovation, the process of domestic substitution of imported devices is intensified, which further promotes the integration of industry enterprises and the process of investment and financing, and the industry's mergers and acquisitions investment will remain active for a long time
.
(Finish)
.
With the support and encouragement of the state for pharmaceutical innovation, the process of domestic substitution of imported devices is intensified, which further promotes the integration of industry enterprises and the process of investment and financing, and the industry's mergers and acquisitions investment will remain active for a long time
.
(Finish)
